Buy & Sell State Street SPDR S&P Biotech ETF (XBI) – State Street SPDR S&P Biotech ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Broad Market / FactorSector
- -8.57%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 19 daysTypical Hold Time
Over the past 52 weeks, State Street SPDR S&P Biotech ETF has traded between a low of $82.1 and a high of $138.67, highlighting its annual price range. Over the past three months, State Street SPDR S&P Biotech ETF has recorded a drawdown of -8.57%, reflecting recent price volatility. On average, investors hold State Street SPDR S&P Biotech ETF for approximately 19 days, indicating typical investor behavior on the platform.
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Most Recent News
Technip Energies, Airbus, Safran, and Tereos form Rebound JV to produce 160,000 tons/year sustainable aviation fuel in France.
Technip Energies, Airbus, Safran, and Tereos have formed a joint venture called Rebound to develop an industrial-scale sustainable aviation fuel (SAF) production project at the Port of Dunkerque, France. Using Alcohol-to-Jet technology, the plant aim...

Technip Energies, Airbus, Safran, and Tereos launch joint venture to produce 160,000 tons of sustainable aviation fuel annually in France.
Technip Energies, Airbus, Safran, and Tereos have formed a joint venture named Rebound to develop a large-scale Sustainable Aviation Fuel (SAF) production facility at the Port of Dunkirk, France. The project aims to produce 160,000 tons of SAF per ye...

Global generic drug market to nearly double to $926.54B by 2034 with 6.55% CAGR driven by cost and chronic disease demand
The global generic drug market is projected to grow from USD 519.11 billion in 2025 to USD 926.54 billion by 2034, at a compound annual growth rate (CAGR) of 6.55%. This growth is driven by increasing demand for cost-effective medicines amid rising c...
